RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice of Allowance From Chinese Patent Office for Treatment and Prevention of Heart Disease
2/8/2013 9:42:40 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it has received a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease. Claims also include uses for restoring heart tissue in those subjects. The patent will expire July 26, 2026.
comments powered by